Greg Clark, the business secretary, heralded the decision as evidence that there is “no place better in Europe to grow a business”. GSK cited Britain’s workforce, technical infrastructure and “competitive corporate tax system” when explaining the move. GlaxoSmithKline is to invest £275 million in the UK in a move the government described as a “clear vote of confidence” in the country after the vote to leave the European Union. The pharmaceutical giant said this morning that Britain remains “an attractive location” for business as it outlined how funding would be ploughed into the production and delivery of medicines. The funding…

Source: The Times July 27, 2016 07:52 UTC